Diagnosis is based on clinical findings, skin biopsy, and laboratory blood tests, and usually requires specialist expertise.
Establishing a diagnosis can be challenging, as the condition can take many different forms in the skin: flat patches, raised plaques, large tumors, and/or marked erythroderma (intense and widespread reddening of the skin).
Early-stage disease is usually managed with skin-directed therapy (topical medications, phototherapy, and localized radiation therapy). If skin disease progresses, or the patient presents with advanced disease, systemic therapies are often necessary (chemotherapy, biologic or immunologic therapy, photopheresis).
Clinical trials may be considered in early and advanced disease. The choice of skin-directed therapy or systemic treatment is usually dependent on both doctor and patient preference, as no one treatment option has been shown to be superior to another.
Prognosis is closely related to the stage at diagnosis. Survival rates in early disease are excellent. However, although treatment may induce remission, patients are expected to relapse after a variable interval and are unlikely to be cured.
Cutaneous T-cell lymphomas (CTCL) make up a heterogeneous group of uncommon disorders characterized by clonal accumulation of T lymphocytes primarily or exclusively in the skin. Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), are the most common subtypes. MF frequently behaves as an indolent lymphoma with good prognosis for early-stage disease, while SS is considered a more aggressive form of the disease, associated with shortened survival.
History and exam
Tim M. Illidge, MD, PhD, FRCR, MRCP, FRCPath
Professor of Targeted Therapy and Oncology
University of Manchester
Manchester Academic Health Sciences Centre
TMI declares that he has no competing interests.
Richard Cowan, MD, FRCR, MRCP
Consultant in Clinical Oncology
Christie NHS Foundation Trust
RC declares that he has no competing interests.
Eileen Parry, MD, MRCP
Tameside Hospital Integrated Care Organisation NHS Trust
EP declares she has no competing interests.
Chris Kelsey, MD
Department of Radiation Oncology
Duke University School of Medicine
CK declares that he has no competing interests.
Robert A. Schwartz, MD, MPH
Professor and Head of Dermatology
Department of Medicine
New Jersey Medical School
RAS declares that he has no competing interests.
Use of this content is subject to our disclaimer